Xenon Pharmaceuticals Inc. $XENE Shares Sold by Polar Capital Holdings Plc

Polar Capital Holdings Plc lessened its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,465,694 shares of the biopharmaceutical company’s stock after selling 81,072 shares during the quarter. Polar Capital Holdings Plc’s holdings in Xenon Pharmaceuticals were worth $110,512,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Sofinnova Investments Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $2,685,000. Verition Fund Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 64.1% in the fourth quarter. Verition Fund Management LLC now owns 93,756 shares of the biopharmaceutical company’s stock valued at $4,202,000 after purchasing an additional 36,639 shares during the last quarter. NEXTBio Capital Management LP acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $8,234,000. Nicholas Investment Partners LP increased its holdings in shares of Xenon Pharmaceuticals by 104.0% in the fourth quarter. Nicholas Investment Partners LP now owns 242,989 shares of the biopharmaceutical company’s stock valued at $10,891,000 after purchasing an additional 123,891 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $763,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a report on Monday, March 9th. Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. HC Wainwright increased their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, Guggenheim reiterated a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $77.20.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $51.99 on Wednesday. The firm has a market capitalization of $5.03 billion, a price-to-earnings ratio of -11.06 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $63.95. The stock has a 50 day moving average of $55.23 and a 200 day moving average of $49.11.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same period in the previous year, the business earned ($0.83) earnings per share. Analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.